TransCon hGH for Growth Hormone Deficiency (enliGHten Trial)

"According to the latest information available on clinicaltrials.gov, this particular study is not recruiting patients at this time. The trial was first posted on December 19th, 2017 and was last updated on October 13th, 2021. Although this particular trial has finished enrolling candidates, there are 108 other trials that are still looking for test subjects."

"This study is no longer recruiting patients. The clinical trial was originally posted on December 19th, 2017 and was last updated on October 13th, 2021. However, there are currently 73 trials searching for patients with pituitary diseases and 35 studies for TransCon hGH that are actively looking for participants."

"TransCon hGH is estimated to be a safe medication, as it has received a score of 3. This is due to the fact that this drug is currently in Phase 3 trials, meaning that there is some efficacy data as well as multiple rounds of safety data supporting its use."

"TransCon hGH has had 35 active trials over the course of 15 years, with the first one being conducted in 2005. So far, these trials have taken place across 170 cities and 45 countries. The initial trial, which was sponsored by BioPartners GmbH, completed Phase 3 drug approval after enrolling 144 patients. In total, 209 clinical trials have been done involving Transcon hGH."

"There are 21 sites currently active for this study, with locations including Charlottesville, New york and Tacoma. If you choose to participate in this trial, please select the site closest to your residence to minimize travel inconvenience."

"TransCon hGH is not just for general surgery patients. It can also help people who are dealing with short stature, open epiphyses, and antiretroviral therapy."

"The first clinical trials studying TransCon hGH took place in 2005 at the Children's Hospital of Philadelphia. As of now, 209 have completed the study. There are 35 active trials being conducted with a large number taking place in Charlottesville, Virginia."

"Among the 154 total trials, this study is for children aged 1 year to 18 years old."

"Researchers are looking for 300 individuals that have a pituitary gland disease and fall in the 1-18 year old age range. The key requirements for participants are as follows: Children who have not taken a permanent break from the study drug in the last trial."